"Front Cover" -- "Nanomedicine in Central Nervous System Injury and Repair" -- "Copyright" -- "Contents" -- "Contributors" -- "Preface" -- "References" -- "Acknowledgments" -- "Chapter One: Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders" -- "1. Introduction" -- "2. Physical Delivery" -- "3. Nonphysical Methods" -- "3.1. Systemic Delivery" -- "3.2. In Vitro Targeting" -- "3.3. In Vivo Proteins, Fusion Proteins, and Modified Enzymes" -- "3.4. Nanoparticle-Based Delivery" -- "4. Conclusion" -- "References" -- "Chapter Two: Impact of Inflammation on the Blood-Neural Barrier and Blood-Nerve Interface: From Review to Therapeutic Preview" -- "1. Introduction" -- "2. Blood-Nerve Interface" -- "3. Mast Cells and the BBB" -- "4. Immune Cell Interactions Amplify Neuroinflammation" -- "5. Neuroinflammation and Aging" -- "6. Mast Cells and Glia as Therapeutic Targets" -- "7. Conclusion and Perspectives" -- "Acknowledgments" -- "Conflict of Interest" -- "References" -- "Chapter Three: Intravenous Administration of Functionalized Magnetic Iron Oxide Nanoparticles Does Not Induce CNS Injury ..." -- "1. Introduction" -- "1.1. Magnetic Iron Oxide Nanoparticles" -- "1.2. Polymer-Coated Iron Oxide Nanoparticles" -- "1.3. Superparamagnetic Iron Oxide Nanoparticles" -- "2. Experimental Procedures" -- "3. SCI Model" -- "4. Nanoparticle Administration" -- "5. Treatment With Cerebrolysin" -- "5.1. Blood-Spinal Cord Barrier/BBB Permeability" -- "5.2. Edema Formation" -- "5.3. Morphological Changes in the Cord" -- "5.4. Experimental Observations" -- "5.4.1. Iron Oxide Nanoparticles Effect on BSCB/BBB Permeability" -- "5.4.2. Morphological Changes Inside the Cord" -- "6. Effects of Cerebrolysin on BBB/BSCB Permeability" -- "6.1. Effects of Cerebrolysin on Neuronal and Glial Cell Damage."

"6.2. Probable Mechanisms of IOMNP-Induced Neurotoxicity" -- "6.3. Cerebrolysin-Induced Neuroprotection" -- "7. Conclusion and Future Perspectives" -- "Acknowledgments" -- "References" -- "Chapter Four: Histaminergic Receptors Modulate Spinal Cord Injury-Induced Neuronal Nitric Oxide Synthase Upregulation and ..." -- "1. Introduction" -- "2. Histamine in the Spinal Cord" -- "3. Histamine and Nitric Oxide Interaction" -- "4. Histamine and the Spinal Cord Microcirculation" -- "5. Histamine and the BSCB Permeability" -- "6. Histamine and Spinal Cord Edema" -- "7. Nanowired Drug Delivery Enhances Neuroprotection" -- "8. Our Investigations on Histamine-Receptor Modulation and nNOS Expression in SCI" -- "8.1. Animals" -- "8.2. Spinal Cord Injury" -- "8.3. Drug Treatments" -- "8.4. TiO2-Nanowired Delivery of Cimetidine and Ranitidine" -- "8.5. Parameters Measured" -- "8.6. BSCB Permeability" -- "8.7. Spinal Cord Edema" -- "8.8. Spinal Cord Blood Flow" -- "8.9. Morphological Analyses" -- "8.10. nNOS Immunohistochemistry" -- "8.11. Histopathology of Nerve Cell Damage" -- "8.12. Statistical Analysis" -- "9. Histamine Receptors Influence Spinal Cord Pathology and nNOS Expression" -- "10. Histamine-Receptor Modulation and BSCB in SCI" -- "11. Histamine-Receptor Modulation and SCBF in SCI" -- "11.1. Correlation Between SCBF and Edema in SCI" -- "12. Histamine-Receptor Modulation and Spinal Cord Edema in SCI" -- "13. Histamine-Receptor Modulation and Neuronal NOS Expression in SCI" -- "14. Histamine-Receptor Modulation and Neuronal Changes in SCI" -- "15. TiO2-Nanowired Delivery of Histamine H2 Receptor Antagonists Has Superior Neuroprotective Effects in SCI" -- "16. Functional Significance of Our Findings" -- "Acknowledgments" -- "References."

"Chapter Five: Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Poten ..." -- "1. Introduction" -- "2. Development" -- "2.1. A Stereological Approach to Assess Neuropathological Hallmarks of PD" -- "2.2. New Morphological Biomarkers of PD Model Progression" -- "2.3. Therapeutics Approaches" -- "2.3.1. Transfected Cells Producing NTF Inside PLGA Microcapsules" -- "2.3.2. PLGA Microspheres Loaded With NTF" -- "2.3.3. NTF Embedded in PLGA Nanoparticles" -- "2.3.3.1. Effects of Blocking the Receptors of NTF" -- "2.3.4. A Noninvasive Therapeutic Strategies: Intranasal Administration" -- "3. Conclusions" -- "Acknowledgments" -- "References" -- "Chapter Six: Novel Treatment Strategies Using TiO2-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With C ..." -- "1. Introduction" -- "2. Histaminergic Mechanism" -- "3. Histamine Actions in the Brain" -- "4. Role of Histamine in AD" -- "5. Histamine as a Mediator for Peripheral Immune Cells" -- "6. Antihistaminergic Drugs" -- "7. Antibodies as Promising Tool for Neurotherapeutic Measures" -- "8. Historical Perspectives on the Use of Antibodies as Therapy" -- "9. Possible Therapeutic Basis of Antibodies" -- "10. Antibodies vs Receptor Antagonist Drugs" -- "11. Antibodies Neutralize Effects of Endogenous Antigens" -- "12. Nanodelivery of Drugs Induces Superior Neuroprotective Effects Than Their Parent Compound" -- "13. Antibodies Therapy in AD" -- "14. Our Own Investigations in AD With Histaminergic Drugs and Antibodies for Neuroprotection" -- "15. AβP Infusion Model of AD" -- "16. Nanowired Delivery of Drugs" -- "17. Parameters Measured" -- "18. BBB Permeability" -- "19. Brain Edema Formation and Volume Swelling" -- "20. AβP (1-40) Immunohistochemistry" -- "20.1. AβP Assay" -- "21. Neuronal Damages."

"22. Glial Fibrillary Acidic Protein Immunohistochemistry" -- "22.1. Tau Protein Assay" -- "23. Our Observations in AD Using Histaminergic Drugs and/or Antibodies" -- "23.1. Proof of Concept" -- "23.1.1. Nanowired Cerebrolysin Reduces AβP and Tau Levels in AD" -- "23.1.2. Infusion of AβP Induces Brain Pathology" -- "23.2. Novel Therapeutic Strategies in AD" -- "23.2.1. Histaminergic Modulation by Drugs in AD Induces Neuroprotection" -- "23.3. Histamine Antibodies Reduces AβP Infusion-Induced Neurotoxicity" -- "24. Nanowired Cerebrolysin Potentiates Histamine Antibodies-Induced Neuroprotection in AD" -- "25. p-Tau Antibodies Reduces Neurotoxicity in AβP Infusion Model of AD" -- "26. Nanowired Cerebrolysin Potentiates p-Tau Antibodies-Induced Neuroprotection in AD" -- "27. Functional Significance of Our Findings" -- "Acknowledgments" -- "References."